From preclinical and first-in-human (FIH) dosage forms like powder-in-capsule (PIC) and powder-in-bottle (PIB), to optimized drug products for late-stage development and market, we offer you a comprehensive and tailored formulation development service. Operating from our state-of-the-art facilities in the U.S. and U.K. and a global team of over 300 formulation and analytical scientists, we work with you to develop the most appropriate formulation based on the physicochemical and biopharmaceutics properties of your molecule.
When a U.S. Biotech company wanted to determine the DCS (Developability Classification System) designation for their small molecule, they approached Quotient Sciences for a tailored formulation development program to quickly go from preclinical to first-in-human.
Learn how we can help you get in the clinic, fast, with formulations developed as either powder-in-capsules (PIC) or powder-in-bottle (PIB). Contact us today to discuss your next project.
Quotient Sciences has more than 30 years of experience developing a breadth of formulations for small molecules and peptides, across a range of indications. With expertise in simple and complex dosage forms, we have formulated over 1,500 molecules. Our unique track record in clinical research, means we know what it takes to develop formulations across the full development pathway from preclinical to late stage.
Want to know more about our formulation capabilities? Access our info sheet
Global VP, Integrated Pharmaceutical Sciences
Executive Director, Pediatric Services
VP, Integrated Development Services
Director, Pharmaceutical Sciences